Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 4/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.39 |
| ▸ | SELE | P16581 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7055711 | 1.00 | IDO1 (0.45) | IDO1PTPN2PTPN1PTPN6CALM1 | |
| SCHEMBL7052847 | 0.98 | IDO1 (0.46) | IDO1PTPN2PTPN1PTPN6CALM1 | |
| SCHEMBL7940753 | 0.89 | IDO1 (0.54) | IDO1PTPN2PTPN1PTPN6ESR1 | |
| SCHEMBL18085581 | 0.87 | PTPN2 (0.41) | IDO1PTPN2PTPN1PTPN6ICAM1 | |
| SCHEMBL19535071 | 0.86 | PTPN2 (0.41) | PTPN2PTPN1PTPN6ICAM1SELE | |
| SCHEMBL23145906 | 0.83 | PTPN2 (0.42) | PTPN2PTPN1PTPN6ICAM1SELE | |
| SCHEMBL16449105 | 0.83 | AGXT (0.48) | IDO1PTPN2PTPN1PTPN6APP | |
| SCHEMBL15602862 | 0.83 | IDO1 (0.48) | IDO1PTPN2PTPN1PTPN6MEN1 | |
| SCHEMBL4217287 | 0.82 | PTPN2 (0.38) | PTPN2PTPN1PTPN6ICAM1SELE | |
| SCHEMBL17527718 | 0.82 | PTPN2 (0.38) | IDO1PTPN2PTPN1PTPN6ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651163-B1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LTD (IN) | 2015-03-04 | — | — | EP | disclosed |
| US-8143366-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2012-03-27 | — | — | US | disclosed |
| US-20100081782-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | EKWURIBE NNOCHIRI N | 2010-04-01 | — | — | US | disclosed |
| US-7625995-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2009-12-01 | — | — | US | disclosed |
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| EP-1651163-A4 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LTD (IN) | 2008-03-26 | — | — | EP | disclosed |
| US-7335751-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2008-02-26 | — | — | US | disclosed |
| US-20060167234-A1 | Aryl carbamate oligomers for hydroilyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2006-07-27 | — | — | US | disclosed |
| EP-1651163-A2 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | Nobex Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005016240-A2 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | NOBEX CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167234-A1 | Aryl carbamate oligomers for hydroilyzable prodrugs and prodrugs comprising same | ALK, OGFR, AOX1 | IDO1 521/4885PTPN2 1279/4885PTPN1 946/4885 |
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | ALK, AOX1, OGFR | IDO1 444/4885PTPN2 1121/4885PTPN1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.